While the first round of the Medicare drug negotiations is complete, and the Pharmaceutical Research and Manufacturers of America's lawsuit filed against the government in 2023 was tossed earlier this year, a federal appeals court in New Orleans reversed the previous dismissal, sending the complaint back to a lower Texas court.
PhRMA asserted the price-setting provisions of the Inflation Reduction Act, which instructed the Centers for Medicare and Medicaid Services in overseeing the Medicare drug price negotiations, were unconstitutional, according to their lawsuit.
The first 10 drugs targeted for drug price negotiations were announced in 2023, and new prices, agreed upon last month with the drug manufacturers, are set to take effect in 2026.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
